NASDAQ:GRFS - Grifols Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$19.08
▼ -0.07 (-0.37%)
1 month | 3 months | 12 months
Get New Grifols Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRFS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Grifols in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $19.08.
Hold
The current consensus among 7 investment analysts is to hold stock in Grifols. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Morgan StanleyReiterated RatingOverweightLow
i
12/9/2020Morgan StanleyReiterated RatingOverweightLow
i
11/6/2020Morgan StanleyReiterated RatingOverweightLow
i
10/30/2020Berenberg BankReiterated RatingBuyLow
i
10/1/2020CitigroupUpgradeSell ➝ NeutralLow
i
9/30/2020Morgan StanleyReiterated RatingOverweightLow
i
7/21/2020Berenberg BankReiterated RatingBuyLow
i
6/23/2020Morgan StanleyReiterated RatingOverweightLow
i
6/10/2020Berenberg BankReiterated RatingBuyMedium
i
6/9/2020CitigroupDowngradeNeutral ➝ SellMedium
i
6/9/2020HSBCUpgradeReduce ➝ HoldMedium
i
6/1/2020BarclaysReiterated RatingOverweightLow
i
4/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
i
3/27/2020Kepler Capital MarketsReiterated RatingHoldMedium
i
3/25/2020CitigroupDowngradeBuy ➝ NeutralLow
i
3/6/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
3/1/2020Kepler Capital MarketsReiterated RatingHoldHigh
i
12/12/2019William BlairReiterated RatingOutperformLow
i
Rating by M. Kaczor at William Blair
12/9/2019Banco SabadellUpgradeSell ➝ BuyMedium
i
10/30/2019Berenberg BankUpgradeBuyLow
i
10/28/2019SantanderUpgradeHold ➝ BuyLow
i
6/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $22.50High
i
2/8/2019Berenberg BankDowngradeBuy ➝ HoldHigh
i
Rating by Tom Jones at Berenberg Bank
1/2/2019Morgan StanleyLower Price TargetUnderweight ➝ Underweight$20.00 ➝ $19.00Low
i
10/30/2018SantanderUpgradeUnderperform ➝ HoldLow
i
10/11/2018Berenberg BankUpgradeHold ➝ BuyMedium
i
10/3/2018UBS GroupDowngradeNeutral ➝ SellHigh
i
10/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $20.00Low
i
6/13/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
6/1/2018BarclaysInitiated CoverageOverweightMedium
i
3/14/2018HSBCUpgradeReduce ➝ HoldLow
i
3/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$23.00 ➝ $22.00Medium
i
11/24/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
i
10/31/2017CitigroupInitiated CoverageBuy ➝ BuyN/A
i
7/4/2017Bank of AmericaReiterated RatingBuyMedium
i
6/30/2017The Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
i
4/6/2017Bank of AmericaInitiated CoverageBuy ➝ BuyLow
i
3/30/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
i
2/27/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/A
i
1/3/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
12/13/2016UBS GroupDowngradeBuy ➝ NeutralN/A
i
6/6/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by James Francescone at Morgan Stanley
5/23/2016UBS GroupUpgradeSell ➝ BuyN/A
i
5/8/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by James Francescone at Morgan Stanley
3/17/2016Nomura SecuritiesInitiated CoverageBuyN/A
i
2/9/2016Berenberg BankUpgradeHold ➝ BuyN/A
i
(Data available from 1/19/2016 forward)
Grifols logo
Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $19.08
$19.08
$19.30

50 Day Range

MA: $18.89
$18.21
$19.60

52 Week Range

Now: $19.08
$13.40
$25.73

Volume

761,360 shs

Average Volume

600,710 shs

Market Capitalization

$13.12 billion

P/E Ratio

17.04

Dividend Yield

0.73%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Grifols?

The following Wall Street sell-side analysts have issued stock ratings on Grifols in the last twelve months: Barclays PLC, Berenberg Bank, Citigroup Inc., HSBC Holdings plc, JPMorgan Chase & Co., Kepler Capital Markets, Morgan Stanley, and Zacks Investment Research.

What is the current price target for Grifols?

0 Wall Street analysts have set twelve-month price targets for Grifols in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Grifols in the next year.

What is the current consensus analyst rating for Grifols?

Grifols currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRFS, but not buy more shares or sell existing shares.

What other companies compete with Grifols?

How do I contact Grifols' investor relations team?

Grifols' physical mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company's listed phone number is 34-93-571-0000 and its investor relations email address is inversores@grifols.com. The official website for Grifols is www.grifols.com.